REGN FY 2010 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$79B

FY 2010 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$459M+21.0% YoY

Gross Profit

$437M95.3% margin

Operating Income

-$97M-21.2% margin

Net Income

-$104M-22.8% margin

EPS (Diluted)

$-1.26

Cash Flow

Operating Cash Flow

$96M

Free Cash Flow

-$3M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$562M

Stockholders' Equity

$528M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$459M	$379M	+21.0%
Gross Profit	$437M	$363M	+20.4%
Operating Income	-$97M	-$74M	-31.5%
Net Income	-$104M	-$68M	-54.0%